BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer

MT Newswires Live

03-20

BriaCell Therapeutics (BCTX) announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue "without any modifications" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.

The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2520456049"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520456049\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520456049?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520456049","market":"fut","top_or_hot":-1,"title":"BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer","media":"MT Newswires Live","content":"<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue \"without any modifications\" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.</p><p>The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-20 20:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue \"without any modifications\" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.</p><p>The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520456049","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520456049","pubTimestamp":1742474760,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BriaCell Therapeutics  announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue \"without any modifications\" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","BCTX":"BriaCell Therapeutics Corp."},"translate_title":"BriaCell Therapeutics表示数据安全监测委员会建议继续进行转移性乳腺癌的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCTX":1,"LENZ":1},"content_text":"BriaCell Therapeutics (BCTX) announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue \"without any modifications\" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}